Integrated Wealth Concepts LLC Acquires 477 Shares of Novo Nordisk A/S (NYSE:NVO)

Integrated Wealth Concepts LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,027 shares of the company’s stock after buying an additional 477 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Novo Nordisk A/S were worth $3,933,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Natixis Advisors LLC raised its stake in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Zions Bancorporation N.A. raised its stake in Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after acquiring an additional 6,726 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after acquiring an additional 37,346 shares during the period. Private Wealth Partners LLC raised its stake in Novo Nordisk A/S by 155.1% in the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock valued at $3,953,000 after acquiring an additional 20,188 shares during the period. Finally, MayTech Global Investments LLC raised its stake in Novo Nordisk A/S by 14.1% in the 3rd quarter. MayTech Global Investments LLC now owns 254,552 shares of the company’s stock valued at $30,309,000 after acquiring an additional 31,475 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on NVO shares. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus target price of $150.40.

Novo Nordisk A/S Stock Performance

NVO opened at $108.96 on Thursday. The firm has a market cap of $488.96 billion, a P/E ratio of 35.26, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The business’s fifty day moving average is $111.82 and its 200-day moving average is $127.46.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.